MATERIAL SAFETY DATA SHEET - Lupin …
msds : 021/00 effective date : 12/06/2007 page 1 of 8 1. identification of the substance and the company 2. composition / information on ingredients
Download MATERIAL SAFETY DATA SHEET - Lupin …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg
lupinpharmaceuticals.comPage 1 of 11 Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg Rx only DESCRIPTION Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker.
Metformin Hydrochloride Extended-Release …
lupinpharmaceuticals.comPage 3 of 22 Distribution Distribution studies with metformin hydrochloride extended-release tablets have not been conducted. However, the apparent volume of distribution (V/F) of metformin following single
MATERIAL SAFETY DATA SHEET - Lupin …
lupinpharmaceuticals.commsds : 050/01 effective date : 25/07/2011 page 3 of 5 6. accidental release measures 7. handling and storage 8. exposure controls / personal protection
Related documents
AUSTRALIAN PRODUCT INFORMATION APO …
www.medicines.org.au5 myopathy and, rarely, rhabdomyolysis have been reported in patients treated with HMG-CoA reductase inhibitors including rosuvastatin.
Simvastatin 5mg, 10mg, 20mg, 40mg and 80mg …
www.medsafe.govt.nzAlthough the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of HMG-CoA reductase inhibitors. The increase in AUC for
149860 - Apo-Rosuvastatin APM
www.promopharm-lb.com2 PrAPO-ROSUVASTATIN Rosuvastatin Calcium Tablets PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form / Strength All Nonmedicinal Ingredients
O PRODUCT INFORMATION Zimstat O - …
www.medicines.org.auZimstat – PRODUCT INFORMATION 3 The pharmacokinetic effects of calcium channel blockers on simvastatin and HMG-CoA reductase inhibitors are
DCPAR Fenofibrate 160mg Film-coated Tablets PL …
www.mhra.gov.ukPAR Fenofibrate 160mg Film-coated Tablets UK/H/1566/01/DC 6 - Hypersensitivity to peanut or arachis oil or soya lecithin or related products,
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.merck.com4 In post-marketing experience with ZETIA, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin prior to initiating ZETIA.